Back to Authors

Manzoor, Nauman F.

https://orcid.org/0000-0002-4299-0474

Mayo Clinic

Virginia Commonwealth University

Citations 3

Outcomes of Near‐Total and Subtotal Resection of Sporadic Vestibular Schwannoma: A Systematic Review and Meta‐Analysis
Kocharyan, Arminé , Daher, Ghazal S. , Curry, Steven D. , Klimara, Miles J. , Coleman, Sarah, Manzoor, Nauman F. , Carlson, Matthew L. , Farrokhian, Nathan , Oleson, Jacob

Otolaryngology–Head and Neck Surgery | June 1, 2024 | Volume: 171 | Issue: 3 | Pages: 642-657

10.1002/ohn.823 Get It

AbstractObjectiveTo evaluate tumor control and facial nerve outcomes after gross‐total (GTR), near‐total (NTR), and subtotal resection (STR) of sporadic vestibular schwannomas (VS).Data SourcesPubMed, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were searched in August 2021 through inception following PRISMA guidelines.Review MethodsEnglish language articles reporting tumor control and facial nerve outcomes of adults (≥18 years) with NTR and STR of VS were evaluated. Study characteristics, demographics data, tumor characteristics, type of surgical intervention, and outcome measures on tumor control and facial nerve function were collected. Pooled relative risk (RR) estimates for tumor recurrence and facial nerve outcomes were calculated and stratified by extent of resection.ResultsFrom an initial search of 2504 articles, 48 studies were included in the analysis. When comparing 1108 patients who underwent NTR to 3349 patients with GTR, the pooled RR of recurrence in the NTR cohort was 2.94 (95% confidence interval [CI] 1.65‐5.24, P = .0002). When comparing 1016 patients who underwent STR to 6171 patients with GTR, the pooled RR of recurrence in the STR cohort was 11.50 (95% CI 6.64‐19.92, P < .0001). Estimates for risk of tumor regrowth for less‐than‐complete resection are presented. There was no elevated risk of adverse facial nerve outcome (defined as House‐Brackmann grade III and above) in each category of extent of resection compared to GTR.ConclusionExtent of resection predicts risk of tumor recurrence/regrowth following microsurgical resection. Favorable facial nerve outcome should be weighed against the increased risk of regrowth and the potential need for further treatment.
Transcanal Endoscopic Repair of an Anterior Epitympanic Encephalocele
Kocharyan, Arminé , Daher, Ghazal S. , Manzoor, Nauman F. , Johnson, Benjamin R. G.

Otology & Neurotology | December 21, 2022 | Volume: 44 | Issue: 2 | Pages: e117-e117

10.1097/mao.0000000000003789 Get It

Radiotherapy and Radiosurgery for Treatment of Residual or Recurrent Endolymphatic Sac Tumor Following Previous Microsurgical Resection
Totten, Douglas J. , Manzoor, Nauman F. , Sherry, Alexander D. , Khattab, Mohamed H. , Link, Michael J. , Cmelak, Anthony J. , Haynes, David S. , Carlson, Matthew L. , Attia, Albert, Sherry, Alexander D , Rivas, Alejandro

Otology & Neurotology | April 9, 2020 | Volume: 41 | Issue: 6 | Pages: e759-e762

10.1097/mao.0000000000002639 Get It

Objective: To report and discuss the effectiveness of stereotactic radiosurgery (SRS) or fractionated radiotherapy (FRT) for tumor control following surgical resection of endolymphatic sac tumors (ELST). Study Design: Retrospective case series. Setting: Multi-institutional academic referral centers. Patients: Patients undergoing surgical resection for ELST followed by SRS or FRT. Intervention(s): Surgical resection followed by radiotherapy. Main Outcome Measures: Local tumor control. Results: Two of the five patients experienced tumor recurrence after gross total microsurgical at 78 and 11 months, respectively. The former patient received salvage 3D conformal radiotherapy (3D-CRT) and while the latter patient underwent three courses of salvage SRS for recurrence, two of which were in-field and was disease-free at last follow up. Two additional patients underwent subtotal tumor resection (STR) followed by intensity-modulated radiation therapy (IMRT) and are currently without disease. One patient underwent STR followed by proton-beam therapy (PBT) and was free of disease at most recent follow-up. Conclusion: SRS/FRT remains a useful adjuvant for treatment of residual or recurrent ELSTs, where the risk of revision microsurgical resection is high.